MARKET

CRIS

CRIS

Curis
NASDAQ
0.8299
-0.0494
-5.62%
After Hours: 0.8440 +0.0141 +1.70% 19:34 09/25 EDT
OPEN
0.8977
PREV CLOSE
0.8793
HIGH
0.9598
LOW
0.8096
VOLUME
290.53K
TURNOVER
--
52 WEEK HIGH
34.91
52 WEEK LOW
0.8096
MARKET CAP
2.01M
P/E (TTM)
-0.0579
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRIS last week (0914-0918)?
Weekly Report · 5d ago
Weekly Report: what happened at CRIS last week (0907-0911)?
Weekly Report · 09/14 09:50
Weekly Report: what happened at CRIS last week (0831-0904)?
Weekly Report · 09/07 09:46
Weekly Report: what happened at CRIS last week (0824-0828)?
Weekly Report · 08/31 09:50
Weekly Report: what happened at CRIS last week (0817-0821)?
Weekly Report · 08/24 09:51
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 08/18 21:06
Analysts Are Bullish on These NA Stocks: Curis (CRIS), Canadian National Railway (CNI)
TipRanks · 08/17 11:40
HC Wainwright & Co. Reiterates Buy on Curis, Maintains $43 Price Target
Benzinga · 08/17 10:14
More
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

Webull offers Curis Inc stock information, including NASDAQ: CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.